Target therapy in metastatic pheochromocytoma: current perspectives and controversies

  • Amrallah A. Mohammed | amrallaabdelmoneem@yahoo.com Oncology Center, King Abdullah Medical City Holy Capital, Saudi Arabia; Medical Oncology Department, Zagazig University, Egypt.
  • Ayman M. El-Shentenawy Clinical Oncology Department, Cairo University, Egypt.
  • Mohamed A. Sherisher Medical Oncology Department, National Cancer Institute, Cairo University, Egypt.
  • Hani M. El-Khatib Oncology Center, King Abdullah Medical City Holy Capital, Egypt.

Abstract

Most of the pheochromocytomas (PCCs) are benign neoplasms, but when they are malignant, they can be difficult to treat. Despite advances in diagnosis and imaging, it remains an untreatable tumor, when metastases develop. A deeper understanding of the alteration of the specific molecular pathways causing malignant PCCs might hopefully lead in the future to the development of multiple molecular-targeted therapies to treat it successfully. Clinical experience and the use of murine models of metastatic PCCs have helped introduce new experimental treatment options which will significantly help the PCCs community explore novel targeted therapies that have already shown promising results in many other types of tumors.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2014-09-23
Info
Issue
Section
Reviews
Keywords:
pheochromocytoma, metastatic, target therapy.
Statistics
  • Abstract views: 2542

  • PDF: 1084
  • HTML: 1320
How to Cite
Mohammed, A. A., El-Shentenawy, A. M., Sherisher, M. A., & El-Khatib, H. M. (2014). Target therapy in metastatic pheochromocytoma: current perspectives and controversies. Oncology Reviews, 8(2). https://doi.org/10.4081/oncol.2014.249